A recent Berkeley Research Group analysis explored the staggering side effects of contract pharmacy expansion on the 340B program over the past 10 years. The misguided guidance that allowed 340B entities to contract with an unlimited number of for-profit retail pharmacies ultimately allowed for-profit vendors, pharmacies and pharmacy benefit managers to exploit the program.